Takeda’s flagship experimental cancer drug ixazomib is a giant leap closer to being filed with regulatory authorities around the globe for multiple myeloma, after turning in a solid performance in late-stage trials.

The Japanese drugmaker said interim data from a Phase III trial show that it improved progression-free survival, with patients taking ixazomib plus lenalidomide/dexamethasone living without their disease worsening for a significantly longer time than those taking placebo plus lenalidomide/dexamethasone.

Ixazomib is an investigational oral proteasome inhibitor - the first to enter Phase III trials - which is being studied in MM, systemic light-chain amyloidosis and other malignancies. 

Takeda failed to divulge further details on findings of the interim analysis at this time, but did note that the data would be submitted to regulators around the world for marketing authorisations.